Jason Kantor
Chief Business Officer Nurix Therapeutics, Inc.
Seminars
Wednesday 9th September 2026
Increasing the Therapeutic Index of a Small Molecule as Precision ADCs: What Have we Learnt so Far?
2:00 pm
- Designing DACs to be a more targeted to oncogenic drivers versus traditional small molecule inhibitors
- Discussing initial proof-of-concept case studies for DACs
- Collaboration potential between antibody engineering and protein degradation companies
